Eupraxia Pharmaceuticals (EPRX) Other Non-Current Assets (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Other Non-Current Assets of $61754.0 for Q1 2026, down 23.03% year-over-year from $80230.0 in Q1 2025, and down 4.01% quarter-over-quarter from $64332.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Other Non-Current Assets for 5 consecutive years, with $61754.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 23.03% year-over-year to $61754.0; the TTM figure through Mar 2026 stood at $61754.0 (down 23.03% YoY), while the FY2025 annual figure was $64332.0, down 20.34% from the prior year.
- Other Non-Current Assets declined to $61754.0 in Q1 2026 per EPRX's latest filing, from $64332.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.1 million in Q3 2024 and bottomed at $2492.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $241235.1 across 5 years, with a median of $77842.0 in 2025.
- On a YoY basis, Other Non-Current Assets climbed as much as 1340.14% in 2025 and fell as far as 92.61% in 2025.
- Eupraxia Pharmaceuticals' Other Non-Current Assets stood at $2492.0 in 2022, then surged by 177.05% to $6904.0 in 2023, then surged by 1069.77% to $80761.0 in 2024, then slipped by 20.34% to $64332.0 in 2025, then dropped by 4.01% to $61754.0 in 2026.
- Business Quant data shows EPRX's Other Non-Current Assets at $61754.0 in Q1 2026, $64332.0 in Q4 2025, and $97597.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 61,754.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,754.00 |
| Dec 31, 2025 | 64,332.00 |
| Sep 30, 2025 | 97,597.00 |
| Jun 30, 2025 | 77,842.00 |
| Mar 31, 2025 | 80,230.00 |
| Dec 31, 2024 | 80,761.00 |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 5,571.00 |
| Dec 31, 2023 | 6,904.00 |
| Dec 31, 2022 | 2,492.00 |